Correlation of lactate dehydrogenase (LDH) isoenzyme profile with outcome in advanced colorectal cancer (CRC) patients (pts) treated with chemotherapy and bevacizumab (BEV) or cediranib (CED).
Jair Bar(Tel Aviv University), Glenwood D. Goss(Ontario Institute for Cancer Research), David Cunningham(Royal Marsden NHS Foundation Trust), Laura A. Pike(Instituto do Câncer do Estado de São Paulo), Juliane M. Jürgensmeier(AstraZeneca (United Kingdom)), Jane Robertson(Cancer Research UK), Stuart Spencer(AstraZeneca (United Kingdom)), Shethah Morgan(AstraZeneca (United Kingdom))
Cited by 1
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
|Science|2018|2.1k